ClinicalTrials.gg
RecruitingNCT06225765Updated Jul 9, 2024

A Prospective Trial Comparing Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) and Conventional Open Thyroidectomy

An interventional study of Transoral endoscopic thyroidectomy vestibular approach (TOETVA) and Traditional Open Thyroidectomy in Benign Thyroid Nodule and Suspicious Malignant Thyroid Nodule, sponsored by Tseung Kwan O Hospital, Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-09.

Sponsored by Tseung Kwan O Hospital, Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To determine if transoral endoscopic thyroidectomy vestibular approach (TOETVA) is a safe and effective procedure compared to traditional open thyroidectomy. Surgical outcomes, patients' satisfaction, voice and swallowing outcomes will be assessed.

Read the detailed description

This is a prospective case control study involving a total 40 patients, with 20 stratified into the test group receiving surgery under transoral endoscopic thyroidectomy vestibular approach (TOETVA) and 20 patients to the control group under traditional open approach. Subjects will be assigned to either group without randomization. Patients satisfactory score, voice and swallowing quality of life outcomes will be assessed using Voice Handicap Index (VHI) and MD Anderson Dysphagia Inventory (MDADI) outcomes. Surgical outcomes, for instance, lower lip numbness, skin injury, operative time, blood loss, vocal cord paralysis, temporary and permanent hypoparathyroidism will be assessed.

02

Conditions studied

  • Benign Thyroid Nodule
  • Suspicious Malignant Thyroid Nodule

Browse trials for

Keywords

  • Thyroid nodule
03

In context

Thyroid Nodule

207 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.

This study's planned enrollment of 40 is below the median of 75 across 121 interventional studies indexed under Thyroid Nodule.

Browse Thyroid Nodule studies →

Lead sponsor

Tseung Kwan O Hospital, Hong Kong is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Benign thyroid nodule less than 4cm
  • Suspicious malignant thyroid nodule less than 2cm, suitable for transoral endoscopic surgery

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years old
  • to general anaesthesia
  • Vulnerable population (e.g. Cognitive impairment, pregnant)
  • Previous anterior neck surgery
  • Previous radiotherapy at the head and neck region
  • Malignant thyroid nodule > 2cm
  • Presence of another , lateral neck, or distant
  • Retrosternal goitre
  • Cervical spine disease precluding extension of the neck
  • Obesity with > 35kg/m2
  • Severe concomitant illness that drastically shortens or increases risk of therapeutic intervention
  • Untreated active infection
  • Non-correctable coagulopathy
  • Emergency surgery
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Transoral endoscopic thyroidectomy vestibular approach (TOETVA)

    Test group receiving surgery under transoral endoscopic thyroidectomy vestibular approach (TOETVA)

    Procedure: Transoral endoscopic thyroidectomy vestibular approach (TOETVA)

  • Active comparator
    Traditional open surgery

    Control group receiving traditional open thyroidectomy

    Procedure: Traditional Open Thyroidectomy

Interventions

  • ProcedureTransoral endoscopic thyroidectomy vestibular approach (TOETVA)

    Remote access thyroid surgery

  • ProcedureTraditional Open Thyroidectomy

    Open thyroidectomy via trans-cervical approach

06

What researchers measure

Primary outcomes

  1. Patient's satisfactory score

    Visual analogue scale 0-10

    Time frame: Post-operative day 1

  2. Patient's satisfactory score

    Visual analogue scale 0-10

    Time frame: Post-operative 2 weeks

  3. Patient's satisfactory score

    Visual analogue scale 0-10

    Time frame: Post-operative 6 months

  4. Post-operative pain

    Visual analogue scale 0-10

    Time frame: Post-operative day 1

  5. Post-operative pain

    Visual analogue scale 0-10

    Time frame: Post-operative 2 weeks

  6. Post-operative pain

    Visual analogue scale 0-10

    Time frame: Post-operative 6 months

  7. Voice quality of life

    Voice Handicap Index - 30 assessing functional, physical and emotional scales

    Time frame: Post-operative day 1

  8. Voice quality of life

    Voice Handicap Index - 30 assessing functional, physical and emotional scales

    Time frame: Post-operative 2 weeks

  9. Voice quality of life

    Voice Handicap Index - 30 assessing functional, physical and emotional scales

    Time frame: Post-operative 6 months

  10. Swallowing quality of life

    MD Anderson dysphagia inventory (MDADI)

    Time frame: Post-operative day 1

  11. Swallowing quality of life

    MD Anderson dysphagia inventory (MDADI)

    Time frame: Post-operative 2 weeks

  12. Swallowing quality of life

    MD Anderson dysphagia inventory (MDADI)

    Time frame: Post-operative 6 months

  13. Complication rate and types

    Lower lip numbness, skin bruising or injury, wound infection, vocal cord paralysis, temporary hypoparathyroidism

    Time frame: Post-operative 2 weeks

  14. Complication rate and types

    Lower lip numbness, vocal cord paralysis, permanent hypoparathyroidism

    Time frame: Post-operative 6 months

Secondary outcomes

  1. Inpatient stay

    Number of days of inpatient stay

    Time frame: An average of 0-2 days after the operation

  2. Operative time

    Minutes

    Time frame: Intra-operatively

  3. Blood loss

    Volume

    Time frame: Intra-operatively

  4. Rate of conversion to open surgery

    Percentage of conversion

    Time frame: Intra-operatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06225765
Lead sponsor
Tseung Kwan O Hospital, Hong Kong
Responsible party
YEUNG WING CHI ZENON (Consultant, Department of Otorhinolaryngology, Head and Neck Surgery, Tseung Kwan O Hospital, Hong Kong) — Principal investigator
First posted
Jan 26, 2024
Start date
Jul 1, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jul 9, 2024

Study contacts

Cherrie Ng
Contact
cherrieng@ent.cuhk.edu.hk
+85235051409
Thomas Hui
Contact
hsc526@ha.org.hk
+85239493549
Jason YK Chan
study director · Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong
Zenon Yeung
principal investigator · Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion